Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating on April 25.
Daina Graybosch’s rating is based on a combination of factors that highlight Gilead Sciences’ strong position in the market despite some challenges. The company’s core business remains stable, with robust demand for its HIV treatments and preventative medications, such as Biktarvy and Descovy. Additionally, Gilead’s liver disease and COVID-19 franchises continue to provide significant cash flow, supported by the promising growth of Livdelzy in treating primary biliary cholangitis.
Despite some downward trends in oncology growth and minor setbacks in cell therapy sales, Gilead’s overall outlook is positive. The company has reiterated its full-year guidance for 2025, which appears achievable given its strong product pipeline and strategic management of macroeconomic factors, such as tariffs and currency fluctuations. These elements contribute to a favorable long-term outlook, justifying the Buy rating.
According to TipRanks, Graybosch is an analyst with an average return of -16.7% and a 29.94% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Merck & Company, BioNTech SE, and Gilead Sciences.
In another report released on April 25, Oppenheimer also reiterated a Buy rating on the stock with a $125.00 price target.